Restoring Mitochondrial Function to Treat Major Diseases
Mitochondrial dysfunction is a critical, yet overlooked, driver of several diseases such as cancer, autoimmune, obesity and aging.
Cryton Biosciences is pioneering a new therapeutic frontier by restoring mitochondrial function, unlocking novel treatments for some of the toughest diseases – starting with cancer.
Transformational Approach to Cancer Therapy
Mitochondria: The Missing Link in The Cancer-Immune Paradigm
For decades, oncology has relied on fragmented strategies that treat tumor growth and immune evasion as separate problems, often falling short in refractory settings. Cryton Biosciences is changing this paradigm by targeting the core of both: the mitochondria.
By restoring regulated mitochondrial function, our proprietary small molecule delivers a powerful dual-action response. We simultaneously induce direct, immunogenic tumor death while restoring the metabolic capacity of exhausted CD8 T cells – creating a unified anti-tumor immunity and overcome the toughest cancers
1. Advances in immunotherapy for MMR proficient colorectal cancer.
2. Estimated patient population based on internal Cryton Biosciences analysis and publicly available epidemiological data.
Unlocking New Potential Treatment Resistant Cancers
Declining Survival Due to Treatment Resistance
Treatment resistance remains a major driver of poor survival in oncology, often leaving patients with exhausted options when traditional chemotherapies and immunotherapies fail. However, emerging science indicates that this resistance could potentially be overcome by restoring mitochondrial function.
Cryton Biosciences is at the forefront of exploring this approach, developing novel therapies designed to bypass historical resistance mechanisms and offer a meaningful path forward for patients facing the toughest cancers
Our Vision
Advance Mitochondrial Medicine Into Next-Gen Cancer Treatment
1945
Chemotherapy
2001
Targeted Therapy
2014
Immunotherapy
Mitotherapy
Our Vision
Advance Mitochondrial Medicine Into Next-Gen Cancer Treatment
1945
Chemotherapy
2001
Targeted Therapy
2014
Immunotherapy
Mitotherapy
Our Team
Anosh S. Gomes
Founder & CEO
Vivek Verma
Academic Co-Founder
James Frederich
Director of Chemistry
Howard Kaufman
Board Member
Anosh S. Gomes
Founder & CEO
- Previously Director of Program Management at Arcus Biosciences.
- Extensive experience in late-stage drug development and commercialization.
- Led end-to end drug development programs in various disease areas, including oncology, neurology and dermatology
- Past: Upsher-Smith Labs and Pfizer
Vivek Verma, PhD
Academic Co-Founder
- Assistant Professor, Hormel Institute, University of Minnesota
- Immunometabolism and cancer biology expert
- Published in Nature and Cancer Discovery
- Past: Georgetown Lombardi Cancer Center
James Frederich, PhD
Director of Medicinal Chemistry
- Associate Professor at Florida State University
- Expert in synthetic chemistry and protein-protein interaction modulators
- Developing several small molecules for startup biotech companies (Cypris Therapeutics, Lento Bio, Resonance Bio)
Howard Kaufman, MD, FACS
Board Member
- CEO of Ankyra Therapeutics (Series B Biotech)
- Led approval of first oncolytic virus (T-VEC) and PD-L1 antibody (avelumab) for Merkel Cell Carcinoma
- Academic appointment at Harvard Medical School; Clinical appointment at Mass General Hospital
- Past: CMO at Compass Therapeutics and Replimune Inc.
Discover How We’re Powering a New Era in Cancer Treatment